Table 2.
Dosage and treatment status with lenvatinib
| Total (n = 703) | Body weight | |||||
|---|---|---|---|---|---|---|
| < 60 kg (n = 323) | ≥ 60 kg (n = 380) | |||||
| Initial dose of lenvatinib, mg | ||||||
| Mean ± SD | 9.02 ± 2.63 | 7.37 ± 1.65 | 10.43 ± 2.49 | |||
| 12 | 265 | (37.7) | 6 | (1.9) | 259 | (68.2) |
| 8 | 353 | (50.2) | 260 | (80.5) | 93 | (24.5) |
| 4 | 85 | (12.1) | 57 | (17.6) | 28 | (7.4) |
| Treatment duration, weeks | ||||||
| Median [min‒max] | 25.3 | [0.3‒68.9] | 21.9 | [0.3‒68.9] | 28.2 | [0.3‒65.4] |
| ≤ 4 | 85 | (12.1) | 40 | (12.4) | 45 | (11.8) |
| > 4 to 8 | 71 | (10.1) | 34 | (10.5) | 37 | (9.7) |
| > 8 to 16 | 112 | (15.9) | 55 | (17.0) | 57 | (15.0) |
| > 16 to 24 | 78 | (11.1) | 44 | (13.6) | 34 | (8.9) |
| > 24 to 36 | 89 | (12.7) | 38 | (11.8) | 51 | (13.4) |
| > 36 | 268 | (38.1) | 112 | (34.7) | 156 | (41.1) |
| Dose modifications at 12 months | ||||||
| Continuing with no dose interruption or reduction | 32 | (4.6) | 17 | (5.3) | 15 | (3.9) |
| Continuing with dose reduction | 46 | (6.5) | 22 | (6.8) | 24 | (6.3) |
| Continuing with dose interruption | 13 | (1.8) | 6 | (1.9) | 7 | (1.8) |
| Continuing with dose reduction and interruption | 84 | (11.9) | 29 | (9.0) | 55 | (14.5) |
| Discontinued | 528 | (75.1) | 249 | (77.1) | 279 | (73.4) |
| RDI during treatment, % | ||||||
| ≥ 80 | 228 | (32.4) | 136 | (42.1) | 92 | (24.2) |
| 60 to < 80 | 155 | (22.0) | 50 | (15.5) | 105 | (27.6) |
| 40 to < 60 | 173 | (24.6) | 88 | (27.2) | 85 | (22.4) |
| < 40 | 147 | (20.9) | 49 | (15.2) | 98 | (25.8) |
Data are presented as n (%) unless otherwise stated. Percentages may not add up to 100.0 because of rounding
RDI relative dose intensity, SD standard deviation